Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic Effects of Androgen-associated Body Mass in Klinefelter Syndrome.

Archives of medicine·2019
Same author

Predictors of Physical Fitness among Southwestern Native American Adolescents at Risk for Diabetes.

Journal of pediatric endocrinology (Jersey City, N.J.)·2017
Same author

Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial.

Molecular psychiatry·2017
Same author

Ten pivotal questions about diabetic ketoacidosis. Answers that clarify new concepts in treatment.

Postgraduate medicine·2001
Same author

Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemic symptoms.

The Journal of clinical endocrinology and metabolism·2001
Same author

A biethnic community survey of cognition in participants with type 2 diabetes, impaired glucose tolerance, and normal glucose tolerance: the New Mexico Elder Health Survey.

Diabetes care·2001

Related Experiment Video

Updated: Jul 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Lispro insulin: benefits and limitations.

M R Burge1, A G Rassam, D S Schade

  • 1University of New Mexico School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism - 5ACC, Albuquerque, NM 87131, USA.

Trends in Endocrinology and Metabolism: TEM
|April 15, 2008
PubMed
Summary

Lispro insulin, a synthetic rapid-acting insulin analog, offers benefits and drawbacks for diabetes management. Optimizing its use requires understanding normal insulin secretion and diabetes pathophysiology.

More Related Videos

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Experiment Videos

Last Updated: Jul 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Insulin therapy is crucial for diabetes mellitus management.
  • Lispro insulin represents a significant advancement as the first synthetic insulin analog.
  • Understanding insulin's physiological role and diabetes pathophysiology is essential for effective treatment.

Purpose of the Study:

  • To highlight the characteristics of Lispro insulin.
  • To discuss the implications of its rapid absorption and short half-life.
  • To emphasize the importance of physiological understanding for optimizing Lispro insulin therapy.

Main Methods:

  • Review of existing literature on insulin physiology and Lispro insulin.
  • Analysis of pharmacokinetic and pharmacodynamic properties of Lispro insulin.
  • Discussion of clinical implications based on physiological principles.

Main Results:

  • Lispro insulin demonstrates rapid absorption and a short half-life compared to endogenous insulin.
  • These properties present both therapeutic advantages (e.g., mealtime control) and potential disadvantages (e.g., risk of hypoglycemia).
  • Effective management necessitates a thorough grasp of glucose homeostasis and insulin action.

Conclusions:

  • Lispro insulin is a valuable tool in diabetes care, offering improved glycemic control potential.
  • Patient outcomes can be maximized by tailoring Lispro insulin regimens to individual physiological needs and disease state.
  • Further research into optimizing insulin analog therapy remains critical for advancing diabetes treatment.